Navigation Links
China Nepstar Chain Drugstore Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Date:3/3/2010

SHENZHEN, China, March 3 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or "the Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2009.

    Fourth Quarter Financial Highlights

    For the quarter ended December 31, 2009:

    -- Same store sales grew 10.5% compared to the same period in 2008

    -- Revenue increased 12.8% to RMB621 million (US$91 million) compared to
       RMB551 million in the fourth quarter of 2008 on an adjusted basis(1)

    -- Operating income rose 13.0% to RMB42 million (US$6 million) compared to
       RMB37 million in the fourth quarter of 2008 on an adjusted basis

    -- Net income was RMB43 million (US$6 million)

    -- Net cash flow from operations was RMB31 million (US$4.5 million)

    (1) Effective January 5, 2009, Nepstar terminated a voting rights
        agreement, which assigned 30% of the total voting rights of Yunnan
        JianZhiJia Chain Drugstore Co. Ltd. ("JZJ") to Nepstar. As of December
        31, 2008 JZJ had 355 drugstore outlets, all of which were located in
        Yunnan province. As a result, Nepstar no longer consolidated JZJ's
        financials beginning in the first quarter of 2009, and the financial
        results of JZJ were accounted for under the equity method.

        To facilitate comparability of figures between periods presented,
        certain financial information for 2008 is shown on an adjusted basis
        in this press release to reflect the accounting impact of the
        termination of the voting rights agreement as if it had been taken
        place in the beginning of the relevant period.

"Our strategy of enhancing product offerings and improving store operation efficiencies is working. Our fourth quarter was highlighted by the continued improvement in same store sales and a healthy recovery in new store openings," commented Mr. Ian Wade, Chief Executive Officer of Nepstar. "As healthcare reform and economic development continued to progress and the size of middle class consumers continued to grow in China, we have seen an increased consumer spending on healthcare products. In the fourth quarter of 2009, we are pleased to see steady increases in our sales of prescription and over-the-counter ("OTC") drugs listed on the Essential Drug List ("EDL"), as well as non-EDL pharmaceutical and nutritional products. Our customers continue to enjoy our selection of products, quality services and the convenience we bring."

Fourth Quarter Results

During the fourth quarter of 2009, the Company opened 156 new stores and closed 14 stores. As of December 31, 2009, Nepstar had a total of 2,479 stores in operation.

Revenue for the fourth quarter of 2009 was RMB621 million (US$91 million), compared to RMB656 million for the same period in 2008, and RMB551 million for same period in 2008 on an adjusted basis.

For the fourth quarter of 2009, revenue contribution from prescription drugs was 27.0%, OTC drugs was 36.4%, nutritional supplements was 19.7%, traditional Chinese herbal products was 3.3% and other products was 13.6%. The higher contribution from sales of prescription drugs was mainly due to the surge of antibiotics sales related to the H1N1 epidemic.

Same store sales (for the 1,577 stores opened before December 31, 2007) for the fourth quarter of 2009 increased by 10.5% from the same period in 2008. The increase was mainly attributable to higher level of prescription and OTC drug sales related to the H1N1 epidemic. The increase was also attributable to the Company's effective marketing campaigns, streamlining of store operations, further optimization of product mix, as well as the general recovery of the Chinese economy.

Nepstar's portfolio of private label products included 1,524 products as of December 31, 2009. Sales of private label products represented approximately 28.7% of revenue and 43.4% of gross profit for the fourth quarter of 2009.

For the fourth quarter of 2009, gross profit was RMB298 million (US$44 million), compared to RMB299 million for the same period in 2008 and RMB272 million for the same period in 2008 on an adjusted basis. Gross margin for the fourth quarter of 2009 was 47.9% compared to 45.6% for the same period in 2008 and 49.4% for the same period in 2008 on an adjusted basis. The decrease in gross margin for the fourth quarter of 2009 compared with the same period in 2008 on an adjusted basis was mainly due to the expansion of the breadth of product offerings and price ranges to maintain competitiveness, and higher branded product sales associated with the H1N1 epidemic.

Sales, marketing and other operating expenses as a percentage of revenue for the fourth quarter of 2009 was 37.1%, compared to 36.2% for the same period in 2008 and 38.6% for the same period in 2008 on an adjusted basis. The decrease in sales, marketing and other operating expenses as a percentage of revenue for the fourth quarter of 2009 compared to the same period in 2008 on an adjusted basis was primarily due to the implementation of effective cost control measures, which resulted in a reduction of headcount, closure of non- performing stores and improved economies of scale.

General and administrative (G&A) expenses as a percentage of revenue for the fourth quarter of 2009 were 4.1%, compared to 3.6% for the same period in 2008 and 4.1% for the same period in 2008 on an adjusted basis.

As a result of the previously mentioned factors, operating income for the fourth quarter of 2009 increased to RMB42 million (US$6 million), compared to RMB38 million for the same period in 2008 and RMB37 million for the same period in 2008 on an adjusted basis. Operating margin improved from 6.1% in the third quarter to 6.7% for the fourth quarter of 2009, compared to 5.9% for the same period in 2008 and 6.7% for the same quarter of 2008 on an adjusted basis.

Interest income for the fourth quarter of 2009 was RMB15 million (US$2 million) compared to RMB27 million for the same period in 2008 both on an actual basis and on an adjusted basis. The decrease in interest income was primarily due to (i) the maturity of a majority of the held-to-maturity investment securities of which the proceeds were placed in bank deposits; (ii) a general decrease of interest rates for bank deposits; and (iii) lower cash balances as a result of the dividend payment of approximately RMB248 million (US$36 million) in May 2009 and a special dividend payment of approximately RMB1,034 million (US$151 million) in fourth quarter of 2009.

Other income in 2009 of RMB9 million (US$1 million) represented a gain on deconsolidation of Yunnan JianZhiJia Chain Drugstore Co. Ltd. ("JZJ"), which equaled to the excess of fair value of the Company's 40% non-controlling interest in JZJ over its book value.

Nepstar's effective tax rate was 35.3% for the fourth quarter of 2009, compared to 27.6% for the same period in 2008 and 27.7% on an adjusted basis. The increase in effective tax rate was primarily due to the deferred tax liability recognized for the excess of the accounting carrying amount over the tax basis of equity interest in JZJ, which amounted to RMB7 million (US$1 million) and accounted for 5.7% of the increase in effective tax rate. Excluding this effect, the effective tax rate was 29.6%, which was due to the relatively higher portion of Nepstar's taxable profits being generated by subsidiaries subject to the PRC statutory tax rate, rather than the preferential rate.

Net income attributable to Nepstar's ordinary shareholders for the fourth quarter of 2009 was RMB43 million (US$6 million), which represented RMB0.20 (US$0.03) basic and diluted earnings per ordinary share and RMB0.40 (US$0.06) basic and diluted earnings per American depositary share ("ADS"). This compares to net income of RMB46 million, which represented RMB0.22 basic and diluted earnings per ordinary share and RMB0.44 basic and diluted earnings per ADS for the same period in 2008. The total number of outstanding ordinary shares of the Company as of December 31, 2009 was 210 million. The weighted average number of ADSs for the fourth quarter of 2009 was 105 million. Each ADS represents two ordinary shares of the Company.

As of December 31, 2009, Nepstar's total cash, cash equivalents and other bank deposits were RMB666 million (US$98 million), restricted cash was RMB765 million (US$112 million), held-to-maturity investment securities were RMB400 million (US$59 million) and total shareholders' equity was RMB1,778 million (US$260 million). Short-term loans stood at RMB470 million (US$69 million), which were the bank borrowings utilized to pay the special dividend, since some investment securities and fixed deposits had not yet matured. Bank deposits of RMB750 million were pledged to obtain the short-term bank loans and credit facilities. As of the date of this press release, the short-term loans have been repaid and the restriction on the pledge bank deposits has been released. The net cash provided by operating activities during the fourth quarter of 2009 was RMB31 million (US$4.5 million).

Fiscal Year 2009 Financial Results

Total revenues for 2009 was RMB2,218 million (US$325 million) compared to RMB2,397 million for 2008, and RMB2,014 million for 2008 on an adjusted basis.

Same store sales (for stores opened before December 31, 2007) for 2009 increased by 2.6% compared to 2008. Since the second quarter of 2009, Nepstar undertook a series of measures to boost same stores sales, including expanding product offerings, adjusting price ranges, streamlining store operation and enhancing marketing campaigns. As a result, same store sales experienced a 3.8% increase in the third quarter, and a 10.5% increase in the fourth quarter, respectively.

In 2009, revenue contribution from prescription drugs was 23.2%, OTC drugs was 36.9%, nutritional supplements was 20.6%, herbal products was 3.6%, and other products was 15.7%.

In 2009, private label products accounted for 29.0% of total revenue and 43.3% of gross profit, respectively. This compares to 28.4% of revenue contribution and 40.6% of gross profit contribution by private label products in 2008 on an adjusted basis.

Gross profit was RMB1.1 billion (US$157 million) for 2009 compared to RMB1.1 billion for 2008 and RMB1.0 billion for 2008 on an adjusted basis. In 2009, gross margin was 48.4% compared to 47.5% in 2008, and 50.8% in 2008 on an adjusted basis. The decrease in gross margin for 2009 compared to 2008 on an adjusted basis was mainly due to the expansion of the breadth of product offerings and more proactive marketing approach to maintain competitiveness.

Income from operations was RMB110 million (US$16 million) for 2009 compared to RMB141 million for 2008, and RMB128 million for 2008 on an adjusted basis. Total operating expenses accounted for 43.5% of total revenue in 2009 as compared to 41.6% in 2008, and 44.4% in 2008 on an adjusted basis. This improvement was largely due to stringent cost control measurement, store efficiency enhancement, and closure of some non-performing stores. As a result, operating margin was improved from 2.6% in the first quarter of 2009, to 4.1% in the second quarter, 6.1% in the third quarter, and 6.7% in the fourth quarter.

Net income attributable to Nepstar's ordinary shareholders was RMB140 million (US$21 million) for 2009 compared to RMB193 million for 2008. The Company reported RMB1.34 (US$0.20) basic earnings per ADS, and RMB1.32 (US$0.20) diluted earnings per ADS for 2009. This compares to RMB1.80 basic earnings per ADS and RMB1.76 diluted earnings per ADS for 2008. In comparison with 2008, Nepstar's lower net income was mainly due to lower interest income, which was attributable to (i) the maturity of a majority of the held-to- maturity investment securities of which the proceeds were placed in bank deposits; (ii) a general decrease of interest rates for bank deposits; and (iii) lower cash balances as a result of the dividend payment of approximately RMB248 million (US$36 million) in May 2009 and special dividend payment of approximately RMB1,034 million (US$151 million) in the fourth quarter of 2009.

On March 16, 2009, Nepstar declared a cash dividend of US$0.35 per ADS, or approximately RMB248 million. The cash dividend was paid in May 2009, to shareholders of record as of the close of business on April 16, 2009.

On August 24, 2009, Nepstar declared a special dividend of US$1.50 per ADS. In November and December 2009, approximately RMB1,034 million (US$151 million) was paid out to shareholders of record as of the close of business on September 25, 2009.

On March 2, 2010, the three independent directors of the Company voluntarily forfeited options to purchase an aggregate of 150,000 ordinary shares of the Company at an exercise price of US$8.10 per ordinary share (US$16.2 per ADS), which were granted in November 2007, and waived the right to certain payments from the Company, which provided for a minimum return from the exercise of such options. In exchange, the Company granted the independent directors an aggregate of 150,000 restricted ordinary shares, which vested immediately. In addition, 50,000 restricted ordinary shares of the Company subject to a vesting schedule were granted to an executive of the Company. The exchange and grants were conducted to provide additional incentive and retention value and was approved by the board of directors of the Company and its compensation committee.

Latest Developments and Business Outlook

In October 2009, Nepstar entered into a definitive agreement with Wenzhou Ren Ren Hao Chain Drugstore Ltd. ("Ren Ren Hao") to acquire the operations of all of its eight drugstores in Wenzhou City. This acquisition represents China Nepstar's first retail presence in Wenzhou, one of the most affluent markets in Zhejiang province in terms of consumption power. The eight Ren Ren Hao drugstores have an average store size of 250 square meters and are located in the city center or in prime locations in nearby major townships. The transaction was completed in February 2010 with the eight stores transferred to Nepstar.

In December 2009, Nepstar entered into a definitive agreement with Beijing Xiang Yun Kang Drugstore, to acquire all of its six drugstores in Beijing. This acquisition will be Nepstar's second acquisition in Beijing. The six drugstores are all located in densely populated residential areas in Beijing. The transaction was completed in February 2010 with the six stores transferred to Nepstar.

Mr. Wade concluded, "In 2010, we will continue to focus on executing our strategy of improving store efficiencies and enhancing product offerings. Our close attention to same store sales, operating margin and free cash flow generation remains unchanged. We will be more active in opening and acquiring stores in areas where economic trends are favorable. With more smaller-sized competitors struggling with margin erosion as a result of healthcare reform in China, the consolidation of the fragmented drugstore industry is bound to accelerate. We believe Nepstar is well-positioned to capture opportunities brought by the evolving competition landscape."

Conference Call Information

The Company will host a conference call, to be simultaneously Web cast, on Wednesday, March 3, 2010 at 8:00 a.m. Eastern Standard Time / 9:00 p.m. Beijing Time. Interested parties may participate in the conference call by dialing +1-877-407-9210 (North America) or +1-201-689-8049 (International) approximately five to ten minutes before the call start time. A live Web cast of the conference call will be available on the Nepstar Web site at http://www.nepstar.cn .

A replay of the call will be available through March 13, 2010 at 11:59 p.m. Eastern Standard Time or March 14, 2010 at 12:59 p.m. Beijing Time. An archived Web cast of the conference call will be available on the Nepstar Web site at http://www.nepstar.cn . Interested parties may access the replay by dialing +1-877-660-6853 (North America) or + 1-201-612-7415 (International) and entering account number 286 and conference ID number 344868.

About China Nepstar Chain Drugstore Ltd.

China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is China's largest retail drugstore chain based on the number of directly operated stores. As of December 31, 2009, the Company had 2,479 stores across 71 cities, one headquarter distribution center and 12 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmacy services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products including consumables. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the robust economic growth in China and to take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Exchange Rate Information

The United States dollar (US$) amounts disclosed in this press release are presented solely for the convenience of the reader. Translations of amounts from RMB into United States dollars for the convenience of the reader were calculated at the certified exchange rate of US$1.00 = RMB6.8259 on December 31, 2009 as set forth in the H.10 weekly statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted into US$ at that rate on December 31, 2009, or at any other date. The percentages stated are calculated based on RMB amounts.

    For more information, please contact:

    In China:
     Lucia Qian
     China Nepstar Chain Drugstore Ltd.
     Vice President, IR
     Phone: +86-755-2641-4065
     Email: qianrt@nepstar.cn

    In the United States:
     Dixon Chen
     Grayling
     Investor Relations
     Tel:   +1-646-284-9403
     Email: dixon.chen@grayling.com

     Ivette Almeida
     Grayling
     Media Relations
     Tel:   +1-646-284-9455
     Email: ivette.almeida@grayling.com


                                   Tables follow




                        China Nepstar Chain Drugstore Ltd.
           Unaudited Condensed Consolidated Statements of Operations
                 (amounts in thousands - except per-share data)

                                                Three-month period ended
                                                      December 31,
                                            2008           2009        2009
                                             RMB            RMB         USD

    Revenue                               655,777        621,355      91,029
    Cost of goods sold                   (356,810)      (323,491)    (47,392)
    Gross profit                          298,967        297,864      43,637
    Sales, marketing and other
     operating expenses                  (237,142)      (230,521)    (33,772)
    General and administrative
     expenses                             (23,399)       (25,664)     (3,760)
    Income from operations                 38,426         41,679       6,105

    Interest income                        26,548         15,183       2,224
    Interest expense                           --         (2,507)       (367)
    Dividend income from cost method
     investments                               --             --          --
    Equity in income of an equity
     method investee                           --          2,410         353
    Other income                               --          8,927       1,308
    Earnings before income tax
     expense                               64,974         65,692       9,623

    Income tax expense                    (17,944)       (23,162)     (3,393)

    Net income                             47,030         42,530       6,230
    Less: Net income attributable to
     noncontrolling interest                 (896)            --          --

    Net income attributable to China
    Nepstar Chain Drugstore Ltd.
     ordinary shareholders                 46,134         42,530       6,230

    Basic earnings per ordinary
     share                                   0.22           0.20        0.03
    Basic earnings per ADR                   0.44           0.40        0.06
    Diluted earnings per ordinary
     share                                   0.22           0.20        0.03
    Diluted earnings per ADR                 0.44           0.40        0.06


                                                      Year ended
                                                      December 31,
                                             2008         2009       2009
                                              RMB          RMB        USD

    Revenue                                2,396,642    2,217,613    324,882
    Cost of goods sold                    (1,257,752)  (1,143,398)  (167,509)
    Gross profit                           1,138,890    1,074,215    157,373
    Sales, marketing and other
     operating expenses                     (898,019)    (858,072)  (125,708)
    General and administrative
     expenses                                (99,495)    (105,652)   (15,478)
    Income from operations                   141,376      110,491     16,187

    Interest income                          121,557       75,335     11,037

    Interest expense                              --       (2,507)      (367)
    Dividend income from cost method
     investments                               1,116        3,776        553
    Equity in income of an equity
     method investee                              --        5,128        751
    Other income                                 113        8,927      1,308
    Earnings before income tax
     expense                                 264,162      201,150     29,469

    Income tax expense                       (64,922)     (61,174)    (8,962)

    Net income                               199,240      139,976     20,507
    Less: Net income attributable to
     noncontrolling interest                  (6,494)          --         --

    Net income attributable to China
    Nepstar Chain Drugstore Ltd.
     ordinary shareholders                   192,746      139,976     20,507

    Basic earnings per ordinary
     share                                      0.90         0.67       0.10
    Basic earnings per ADR                      1.80         1.34       0.20
    Diluted earnings per ordinary
     share                                      0.88         0.66       0.10
    Diluted earnings per ADR                    1.76         1.32       0.20



                        China Nepstar Chain Drugstore Ltd.
                 Unaudited Condensed Consolidated Balance Sheets
                              (amounts in thousands)

                                          As of                As of
                                       December 31,          December 31,
                                          2008                  2009
                                           RMB             RMB          USD
    ASSETS
    Current assets
    Cash, cash equivalents and
     other bank deposits                1,197,884        666,012      97,571
    Restricted cash                            --        765,000     112,074
    Held-to-maturity investment
     securities                           641,000        400,000      58,600
    Accounts receivable, net of
     allowance for
     doubtful accounts                     88,136         72,561      10,630
    Prepayments for purchase of
     merchandise paid to
     related parties                       70,306         38,102       5,582
    Amounts due from related
     parties                                7,244          7,306       1,070
    Prepaid expenses, deposits
     and other current assets             178,354        144,154      21,119
    Inventories                           373,689        369,775      54,172
    Deferred income taxes                  15,863          6,907       1,012
    Total current assets                2,572,476      2,469,817     361,830

    Non-current assets
    Long-term bank deposits               200,000             --          --
    Held-to-maturity investment
     securities                           400,000             --          --
    Property and equipment, net           240,396        204,710      29,990
    Deposits for purchases of
     properties paid to
     related parties                        2,100             --          --
    Rental deposits                        28,873         38,557       5,649
    Cost method investments                12,638         12,638       1,851
    Equity method investment                   --         29,343       4,299
    Land use right                             --          8,622       1,263
    Intangible assets, net                  2,390            725         106
    Goodwill                               35,177         40,462       5,928
    Deferred income taxes                   4,723          2,914         427
    Other non-current assets                   --         12,788       1,874
    Total non-current asset               926,297        350,759      51,387

    Total Assets                        3,498,773      2,820,576     413,217

    LIABILITIES AND SHAREHOLDERS'
     EQUITY
    Current liabilities
    Short-term bank loans                      --        470,000      68,855
    Accounts payable                      267,250        313,794      45,972
    Amounts due to related
     parties                               64,200         12,533       1,836
    Accrued expenses and other
     payables                             123,905        121,645      17,821
    Income tax payable                     35,344         38,599       5,655
    Dividend payable                           --         38,631       5,659
    Total current liabilities             490,699        995,202     145,798

    Non-current liabilities
    Deferred income                        14,992         27,002       3,956
    Deferred income taxes                  10,443         20,640       3,024
    Total non-current liabilities          25,435         47,642       6,980

    Total liabilities                     516,134      1,042,844     152,778

    Shareholders' equity
    Share capital                             165            166          24
    Additional paid-in capital          2,823,668      1,605,762     235,245
    Accumulated other
     comprehensive loss                   (38,009)       (38,485)     (5,638)
    Retained earnings                     173,650        210,289      30,808
    Total China Nepstar Chain
     Drugstore Ltd.
     shareholders' equity               2,959,474      1,777,732     260,439
    Non-controlling interest               23,165             --          --
    Total shareholders' equity          2,982,639      1,777,732     260,439

    Total liabilities and
     shareholders' equity               3,498,773      2,820,576     413,217



                        CHINA NEPSTAR CHAIN DRUGSTORE LTD.
                   Unaudited Consolidated Cash Flow Information
                              (amounts in thousands)

                       Three-month period ended            Year ended
                              December 31,                 December 31,
                     2008           2009            2008            2009
                      RMB        RMB      USD        RMB        RMB      USD

    Cash flows
     provided by
     operating
     activities     46,027     30,742    4,504      66,269    295,280   43,258

    Cash flows
     provided by/
     (used in)
     investing
     activities   (959,832)   (18,802)  (2,750) (1,671,009)   652,720   95,624

    Cash flows
     used in
     financing
     activities    (79,267)  (562,611) (82,423)   (206,955)  (814,891)(119,381)



                       China Nepstar Chain Drugstore Ltd.
               Key Financials Presented with Adjusted Comparisons
                     (amounts in thousands - except ratios)

                             Three-month ended              Year ended
                                December 31,               December 31,
                          Adjusted 2008    2009      Adjusted 2008    2009
                               RMB          RMB            RMB         RMB

    Revenue                     550,771   621,355       2,013,648  2,217,613
    Gross profit                272,245   297,864       1,021,957  1,074,215
    Gross margin                  49.4%     47.9%           50.8%      48.4%
    Income from operations       36,882    41,679         128,180    110,491
    Operating margin               6.7%      6.7%            6.4%       5.0%
    Interest income              26,536    15,183         121,527     75,335
    Net income attributable
     to China Nepstar Chain
     Drugstore Ltd. ordinary
     shareholders                46,134    42,530         192,746    139,976
    Net margin                     8.4%      6.8%            9.6%       6.3%

                               Adjusted
                                As of     As of
                               December  December
                                  31,       31,
                                 2008      2009
                                  RMB       RMB

    Cash, cash equivalents
     and other bank deposits  1,190,873   666,012
    Total held-to-maturity
     investment securities    1,041,000   400,000
    Long-term bank deposits     200,000        --
    Total assets              3,383,238 2,820,576
    Total liabilities           423,764 1,042,844
    Total shareholders'
     equity                   2,959,474 1,777,732

    Adjusted financial information is presented to show the accounting impact
    of the termination of the JZJ voting rights agreement as if it had been
    taken place in the beginning of January 2008 or as of December 31, 2008,
    where applicable.

SOURCE China Nepstar Chain Drugstore Ltd.

Back to top

RELATED LINKS
http://www.nepstar.cn

'/>"/>

SOURCE China Nepstar Chain Drugstore Ltd.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. China Nepstar Chain Drugstore Announces Annual Dividend
2. Chinas leading electronic systems design event to highlight next-generation medical, automotive and green power technologies
3. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
4. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
5. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
6. Candela Receives Registration Approval to Market Its Best-in-Class GentleMax and Alex TriVantage Lasers in China
7. Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China
8. Chinas Basic Medical Insurance to Cover Sinobiopharmas Flagship Product
9. China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters
10. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
11. China Sky One Medical, Inc.s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):